SCHEMBL442076

SCHEMBL442076

COc1cc(CNC(=O)c2cnc(OC(C)C(F)(F)F)c(-c3ccc(Cl)cc3)n2)on1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GABRA5 P31644 3/20 0.39
POLB P06746 1/20 0.39
CNR1 P21554 3/20 0.39
KMT2A Q03164 2/20 0.38
S1PR1 P21453 1/20 0.38
S1PR3 Q99500 1/20 0.38
S1PR5 Q9H228 1/20 0.38
MAPK1 P28482 1/20 0.37
THRB P10828 1/20 0.37
MEN1 O00255 1/20 0.37
CNR2 P34972 2/20 0.37
JAK2 O60674 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL412187 1.00 NPC1 (0.43) NPC1RAB9ALMNASMN1; SMN2GABRA5
SCHEMBL444416 0.85 MAPT (0.40) SMN1; SMN2GABRA5CNR1S1PR1S1PR3
SCHEMBL412249 0.85 MAPT (0.40) SMN1; SMN2GABRA5CNR1S1PR1S1PR3
SCHEMBL441620 0.85 CNR1 (0.45) NPC1RAB9ALMNASMN1; SMN2GABRA5
SCHEMBL410622 0.85 CNR1 (0.45) NPC1RAB9ALMNASMN1; SMN2GABRA5
SCHEMBL444341 0.83 NPC1 (0.45) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL411573 0.83 NPC1 (0.45) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL440915 0.83 NPC1 (0.44) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL412022 0.83 NPC1 (0.44) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL441921 0.80 ALDH1A1 (0.47) NPC1RAB9ALMNASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2613785-B1 HETEROARYLMETHYL AMIDES HOFFMANN LA ROCHE (CH) 2015-07-29 EP claimed
US-20120065212-A1 HETEROARYLMETHYL AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-15 US claimed
EP-2613785-B1 HETEROARYLMETHYL AMIDES HOFFMANN LA ROCHE (CH) 2015-07-29 EP disclosed
US-9090599-B2 Heteroarylmethyl amides HOFFMANN-LA ROCHE INC. (US) 2015-07-28 US disclosed
US-20140194436-A1 HETEROARYLMETHYL AMIDES HOFFMANN-LA ROCHE INC. (US) 2014-07-10 US disclosed
US-8729105-B2 Heteroarylmethyl amides HOFFMANN LA-ROCHE INC. (US) 2014-05-20 US disclosed
US-20120065212-A1 HETEROARYLMETHYL AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194436-A1 HETEROARYLMETHYL AMIDES APOB, LDLR, HMGCR NPC1 16/4885RAB9A 840/4885LMNA 886/4885
US-20120065212-A1 HETEROARYLMETHYL AMIDES APOB, LDLR, HMGCR NPC1 16/4885RAB9A 840/4885LMNA 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.